Breaking News Instant updates and real-time market news.

TEVA

Teva

$46.01

-0.28 (-0.60%)

07:40
10/03/16
10/03
07:40
10/03/16
07:40

Teva shares suffering from lack of catalysts, says Wells Fargo

Wells Fargo analyst David Maris attributes the continued slide in Teva (TEVA) shares largely to negative sector news such as the drug pricing debate, fears on generic pricing, and Mylan's (MYL) EpiPen issue, but also thinks the slide has been made worse by Teva's lack of near-term catalysts. Additionally, the ongoing Copaxone generic trial and Teva's recently filed suit against Rimsa's founders over allegedly being misled by the Mexican pharmaceutical company have added to the pressure, Maris noted. Maris acknowledges there may be "no notable catalysts" for the rest of the year for Teva, but he thinks it should be a "robust 2017" for the company and keeps an Outperform rating on the shares.

  • 06

    Nov

  • 15

    Nov

TEVA Teva
$46.01

-0.28 (-0.60%)

09/02/16
09/02/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. MercadoLibre (MELI) upgraded to Overweight from Neutral at JPMorgan by analyst Andre Baggio, who said the Brazilian marketplace is thriving, and MercadoLibre is gaining market share. 2. Teva (TEVA) upgraded to Outperform from Perform at Oppenheimer by analyst Rohit Vanjani, who points out that the validity of Teva's Copaxone patents now lies with the District Court decision after the inter partes reviews by the USPTO. Vanjani believes the court ruling, which will likely come in early 2017, is the more important of the two, with a higher hurdle to invalidate the patents. 3. Pioneer Energy (PES) upgraded to Buy from Hold at Jefferies by analyst Brad Handler, who argues that the 24% pullback in shares since the early July peak provides an attractive valuation. The analyst believes Pioneer's covenant risk can be managed and raised his price target for the shares to $6 from $5. 4. Amec Foster Wheeler (AMFW) upgraded to Buy from Neutral at BofA/Merrill. 5. Mitsubishi UFJ (MTU) upgraded to Outperform from Neutral at Daiwa. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
09/29/16
OTRG
09/29/16
INITIATION
OTRG
Positive
Teva initiated with a Positive at OTR Global

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.